Logo image
Evaluating the tumour detection efficacy of [18F]Fluorthanatrace positron emission tomography in a metastatic lung cancer animal model
期刊文章   同儕審查

Evaluating the tumour detection efficacy of [18F]Fluorthanatrace positron emission tomography in a metastatic lung cancer animal model

Chi-Chang Weng, Che-Hsing Chu, Faria Khan, Shihong Li, Hsiaoju Lee, Robert H. Mach, Ching-Han Hsu 和 Yi-Hsiu Chung
Nuclear medicine and biology, 卷.158, 頁.109642
01/07/2026
PMID: 42263446
Web of Science ID: WOS:001796819400001

摘要

Life Sciences & Biomedicine Radiology, Nuclear Medicine & Medical Imaging Science & Technology
Lung cancer is a leading cause of cancer-related mortality worldwide, with high metastatic potential and limited imaging tools for guiding targeted therapies. Poly(ADP-ribose) polymerase (PARP)-1 is overexpressed in multiple malignancies and represents a promising target for molecular imaging. Here, we evaluated the feasibility and specificity of [F-18]Fluorthanatrace ([F-18]FTT), a radiolabeled PARP inhibitor analogue, for noninvasive detection of lung cancer metastases in a syngeneic mouse model. Lung metastases were established by intravenous injection of LL/2 cells into C57BL/6 mice, followed by micro-CT and dynamic/static PET imaging. [F-18]FTT showed high radiochemical purity (>99%) and remained stable in vitro. Dynamic PET identified 30-45 min postinjection as the optimal imaging window (tumour-to-lung ratio: 2.15 +/- 0.10). Tumour uptake was significantly reduced by pre-administration of olaparib, confirming PARP-1-specific binding. Ex vivo autoradiography and immunohistochemistry demonstrated colocalization of tracer uptake with PARP-1 expression. Together, these results support the translational potential of [F-18]FTT PET imaging for detecting PARP-1-expressing lung metastases in precision oncology.

相關連結

指標

1 檢視次數

詳細資料

Logo image